What are non target lesion in RECIST criteria for response to chemothe

What are non target lesion in RECIST criteria for response to chemotherapy in breast cancer

Reading File

Finding Sources

Searching the Web

RECIST 1.1 non-target lesion criteria definition response assessment

Reading File

Finding Sources

I now have comprehensive information to provide a detailed answer. Let me compile everything.

Non-Target Lesions in RECIST 1.1 Criteria

Non-target lesions are all lesions (or sites of disease) that are not selected as target lesions at baseline. This includes:

All non-measurable lesions (lesions too small to measure reliably: <10 mm on CT/MRI for non-nodal lesions, or lymph nodes with short axis <15 mm but still pathological)
Pathological lymph nodes not selected as target lesions
Lesions that are measurable but were not chosen as target lesions (RECIST allows up to 5 total target lesions, max 2 per organ)
Sites of disease such as leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast cancer, lymphangitic spread, and abdominal masses not confirmed by imaging

Unlike target lesions, non-target lesions do not require measurements. They are tracked qualitatively as:

Status	Meaning
Present	Lesion still visible but not progressing
Absent	Lesion has disappeared
Unequivocal progression	Clear, substantial worsening (rare)

Response	Definition
Complete Response (CR)	Disappearance of ALL non-target lesions AND normalization of tumor marker levels. All lymph nodes must be non-pathological in size (<10 mm short axis).
Non-CR / Non-PD	Persistence of one or more non-target lesion(s) AND/OR maintenance of tumor marker levels above the normal limit. This is the most common category - it means the disease has neither fully resolved nor clearly progressed.
Progressive Disease (PD)	Unequivocal progression of existing non-target lesions.

This is the most nuanced part of non-target assessment:

A modest increase in size of one or more non-target lesions is NOT sufficient to declare progression
There must be an overall level of substantial worsening such that - even if target lesions show SD or PR - the overall tumor burden has clearly increased enough to warrant stopping therapy
Progression based solely on non-target disease (when target lesions are stable or responding) is extremely rare in practice
The appearance of new lesions always constitutes PD, regardless of non-target or target status

Target Response	Non-Target Response	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/Non-PD	No	PR
CR	Not evaluated	No	PR
PR	Non-PD or not evaluated	No	PR
SD	Non-PD or not evaluated	No	SD
PD	Any	Any	PD
Any	PD	Any	PD
Any	Any	Yes	PD

Bone metastases are common in breast cancer and are classified as non-target lesions if blastic (non-measurable) - only lytic lesions with a measurable soft tissue component qualify as target lesions
Inflammatory breast cancer (skin involvement, dermal lymphatics) is considered non-measurable and tracked as a non-target lesion
Lymphangitic carcinomatosis (lung/skin) is non-measurable - non-target
Pleural/pericardial effusion is non-measurable - non-target
Tumor markers (CA 15-3, CA 27-29) are factored into non-target CR assessment (must normalize for CR)
Brain metastases: if previously irradiated, may not count as new lesions; if new and unirradiated, constitute PD

Non-target lesions can never "switch" to target lesions during the course of treatment - the lesion designations at baseline are fixed
Multiple non-target lesions in the same organ can be recorded as a single line item (e.g., "multiple liver metastases")
A lesion that was a target lesion and becomes "too small to measure" is recorded as 0 mm (or 5 mm by convention) - it does not become a non-target lesion
Non-target lymph nodes should only be designated as such if short axis is ≥1 cm; nodes <1 cm cannot achieve formal CR by RECIST definition if listed as non-target

This is a shared conversation. Sign in to Orris to start your own chat.